[Renal cell carcinoma]

Area of Science:

• Oncology
• Medical treatment of renal cell carcinoma

Background:

• Cytokine therapies like interferon and interleukin-2 were traditional treatments for advanced renal cell carcinoma.
• The advent of molecular targeted medicine has significantly transformed treatment paradigms.

Purpose of the Study:

• To review the evolution of renal cell carcinoma treatment from cytokine therapies to molecular targeted medicine.
• To highlight the current mainstream targets and emerging therapeutic pathways.

Main Methods:

• Review of existing literature on advanced renal cell carcinoma treatments.
• Analysis of the efficacy of vascular endothelial growth factor pathway inhibitors.
• Examination of alternative molecular pathways and their targeted inhibitors.

Main Results:

• Vascular endothelial growth factor (VEGF) and its receptor inhibitors are current mainstream treatments.
• Inhibitors targeting alternative molecular pathways have demonstrated established efficacy.
• The field anticipates the introduction of novel molecular targeted therapies.

Conclusions:

• Molecular targeted medicine represents a significant advancement in treating advanced renal cell carcinoma.
• Personalized medicine, tailored to individual patient conditions, is crucial for optimal treatment in renal cell carcinoma.
• Continued research and development are expected to yield even more advanced therapeutic options.